TSH-activated signaling pathways in thyroid tumorigenesis

Molecular and Cellular Endocrinology

Volumn 213, Issue 1, 2003, Pages 31-45

  Rivas, Marcos ^a   Santisteban, Pilar ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Thyrocyte; Thyrotropin; Tumorigenesis

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOLIPASE D; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P70; RAP PROTEIN; RAS PROTEIN; S6 KINASE; THYROTROPIN; THYROTROPIN RECEPTOR; WORTMANNIN;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN 3T3; CONFERENCE PAPER; DOG; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; MITOGENESIS; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PATHOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID CELL; TRANSGENIC MOUSE;

EID: 1242318752     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2003.10.029     Document Type: Conference Paper

References (224)

1. al-Alawi N., Rose D.W., Buckmaster C., Ahn N., Rapp U., Meinkoth J., Feramisco J.R. Thyrotropin-induced mitogenesis is Ras dependent but appears to bypass the Raf-dependent cytoplasmic kinase cascade. Mol. Cell Biol. 15:1995;1162-1168.
2. Albright C.F., Giddings B.W., Liu J., Vito M., Weinberg R.A. Characterization of a guanine nucleotide dissociation stimulator for a ras-related GTPase. EMBO J. 12:1993;339-347.
3. Allgeier A., Offermanns S., Van Sande J., Spicher K., Schultz G., Dumont J.E. The human thyrotropin receptor activates G-proteins Gs and Gq/11. J. Biol. Chem. 269:1994;13733-13735.
4. Allgeier A., Laugwitz K.L., Van Sande J., Schultz G., Dumont J.E. Multiple G-protein coupling of the dog thyrotropin receptor. Mol. Cell Endocrinol. 127:1997;81-90.
5. Altschuler D.L., Ribeiro-Neto F. Mitogenic and oncogenic properties of the small G protein Rap1b. Proc. Natl. Acad. Sci. U.S.A. 95:1998;7475-7479.
6. Ambesi-Impiombato F.S., Parks L.A., Coon H.G. Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc. Natl. Acad. Sci. U.S.A. 77:1980;3455-3459.
7. Ariga M., Nedachi T., Akahori M., Sakamoto H., Ito Y., Hakuno F., Takahashi S. Signalling pathways of insulin-like growth factor-I that are augmented by cAMP in FRTL-5 cells. Biochem. J. 348(Pt 2):2000;409-416.
8. Armstrong R., Wen W., Meinkoth J., Taylor S., Montminy M. A refractory phase in cyclic AMP-responsive transcription requires down regulation of protein kinase A. Mol. Cell Biol. 15:1995;1826-1832.
9. Avvedimento V.E., Musti A.M., Ueffing M., Obici S., Gallo A., Sanchez M., DeBrasi D., Gottesman M.E. Reversible inhibition of a thyroid-specific trans-acting factor by Ras. Genes Dev. 5:1991;22-28.
10. Bachrach L.K., Eggo M.C., Mak W.W., Burrow G.N. Phorbol esters stimulate growth and inhibit differentiation in cultured thyroid cells. Endocrinology. 116:1985;1603-1609.
11. Barbacid M. Ras genes. Annu. Rev. Biochem. 56:1987;779-827.
12. Bar-Sagi D., Hall A. Ras and Rho GTPases: a family reunion. Cell. 103:2000;227-238.
13. Becks G.P., Logan A., Phillips I.D., Wang J.F., Smith C., DeSousa D., Hill D.J. Increase of basic fibroblast growth factor (FGF) and FGF receptor messenger RNA during rat thyroid hyperplasia: temporal changes and cellular distribution. J. Endocrinol. 142:1994;325-338.
14. Bellacosa A., Testa J.R., Staal S.P., Tsichlis P.N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 254:1991;274-277.
15. Berridge M.J. Inositol trisphosphate and calcium signalling. Nature. 361:1993;315-325.
16. Biebermann H., Schoneberg T., Hess C., Germak J., Gudermann T., Gruters A. The first activating TSH receptor mutation in transmembrane domain 1 identified in a family with nonautoimmune hyperthyroidism. J. Clin. Endocrinol. Metab. 86:2001;4429-4433.
17. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature. 411:2001;355-365.
18. Bone E.A., Alling D.W., Grollman E.F. Norepinephrine and thyroid-stimulating hormone induce inositol phosphate accumulation in FRTL-5 cells. Endocrinology. 119:1986;2193-2200.
19. Bos J.L., de Rooij J., Reedquist K.A. Rap1 signalling: adhering to new models. Nat. Rev. Mol. Cell Biol. 2:2001;369-377.
20. Bourne H.R., Sanders D.A., McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature. 348:1990;125-132.
21. Brabant G., Maenhaut C., Kohrle J., Scheumann G., Dralle H., Hoang-Vu C., Hesch R.D., von zur Muhlen A., Vassart G., Dumont J.E. Human thyrotropin receptor gene: expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol. Cell Endocrinol. 82:1991;R7-R12.
22. Brandi M.L., Rotella C.M., Mavilia C., Franceschelli F., Tanini A., Toccafondi R. Insulin stimulates cell growth of a new strain of differentiated rat thyroid cells. Mol. Cell Endocrinol. 54:1987;91-103.
23. Brazil D.P., Hemmings B.A. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci. 26:2001;657-664.
24. Broecker M., Mayr G.W., Derwahl M. Suppression of thyrotropin receptor-G protein-phospholipase C coupling by activation of protein kinase C in thyroid carcinoma cells. Endocrinology. 138:1997;3787-3796.
25. Brunetti A., Chiefari E., Filetti S., Russo D. The 3′,5′- cyclic adenosine monophosphate response element binding protein (CREB) is functionally reduced in human toxic thyroid adenomas. Endocrinology. 141:2000;722-730.
26. Brunn G.J., Williams J., Sabers C., Wiederrecht G., Lawrence J.C. Jr., Abraham R.T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15:1996;5256-5267.
27. Burikhanov R., Coulonval K., Pirson I., Lamy F., Dumont J.E., Roger P.P. Thyrotropin via cyclic AMP induces insulin receptor expression and insulin Co-stimulation of growth and amplifies insulin and insulin-like growth factor signaling pathways in dog thyroid epithelial cells. J. Biol. Chem. 271:1996;29400-29406.
28. Camps M., Carozzi A., Schnabel P., Scheer A., Parker P.J., Gierschik P. Isozyme-selective stimulation of phospholipase C-beta 2 by G protein beta gamma-subunits. Nature. 360:1992;684-686.
29. Cass L.A., Meinkoth J.L. Differential effects of cyclic adenosine 3′, 5′-monophosphate on p70 ribosomal S6 kinase. Endocrinology. 139:1998;1991-1998.
30. Cass L.A., Meinkoth J.L. Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation. Oncogene. 19:2000;924-932.
31. Cass L.A., Summers S.A., Prendergast G.V., Backer J.M., Birnbaum M.J., Meinkoth J.L. Protein kinase A-dependent and -independent signaling pathways contribute to cyclic AMP-stimulated proliferation. Mol. Cell Biol. 19:1999;5882-5891.
32. Castagna M., Takai Y., Kaibuchi K., Sano K., Kikkawa U., Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 257:1982;7847-7851.
33. Cheng G., Meinkoth J.L. Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells. Oncogene. 20:2001;7334-7341.
34. Cheng G., Lewis A.E., Meinkoth J.L. Ras stimulates aberrant cell cycle progression and apoptosis in rat thyroid cells. Mol. Endocrinol. 17:2003;450-459.
35. Chou M.M., Blenis J. The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Curr. Opin. Cell Biol. 7:1995;806-814.
36. Ciullo I., Diez-Roux G., Di Domenico M., Migliaccio A., Avvedimento E.V. cAMP signaling selectively influences Ras effectors pathways. Oncogene. 20:2001;1186-1192.
37. Cobellis G., Missero C., Di Lauro R. Concomitant activation of MEK-1 and Rac-1 increases the proliferative potential of thyroid epithelial cells, without affecting their differentiation. Oncogene. 17:1998;2047-2057.
38. Cocks H.C., Ramsden J.D., Watkinson J.C., Eggo M.C. Thyroid stimulating hormone increases angiogenic growth factor expression in rat thyrocytes. Clin. Otolaryngol. 25:2000;570-576.
39. Correze C., Blondeau J.P., Pomerance M. The thyrotropin receptor is not involved in the activation of p42/p44 mitogen-activated protein kinases by thyrotropin preparations in Chinese hamster ovary cells expressing the human thyrotropin receptor. Thyroid. 10:2000;747-752.
40. Corvilain B., Van Sande J., Dumont J.E., Vassart G. Somatic and germline mutations of the TSH receptor and thyroid diseases. Clin. Endocrinol. (Oxford). 55:2001;143-158.
41. Coso O.A., Teramoto H., Simonds W.F., Gutkind J.S. Signaling from G protein-coupled receptors to c-Jun kinase involves beta gamma subunits of heterotrimeric G proteins acting on a Ras and Rac1-dependent pathway. J. Biol. Chem. 271:1996;3963-3966.
42. Coulonval K., Vandeput F., Stein R.C., Kozma S.C., Lamy F., Dumont J.E. Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochem. J. 348(Pt 2):2000;351-358.
43. Cowley S., Paterson H., Kemp P., Marshall C.J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 77:1994;841-852.
44. D'Arcangelo D., Silletta M.G., Di Francesco A.L., Bonfitto N., Di Cerbo A., Falasca M., Corda D. Physiological concentrations of thyrotropin increase cytosolic calcium levels in primary cultures of human thyroid cells. J. Clin. Endocrinol. Metab. 80:1995;1136-1143.
45. Darnell J.E. Jr. STATs and gene regulation. Science. 277:1997;1630-1635.
46. Davis R.J. Transcriptional regulation by MAP kinases. Mol. Reprod. Dev. 42:1995;459-467.
47. de Rooij J., Zwartkruis F.J., Verheijen M.H., Cool R.H., Nijman S.M., Wittinghofer A., Bos J.L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. 396:1998;474-477.
48. De Vita G., Berlingieri M.T., Visconti R., Castellone M.D., Viglietto G., Baldassarre G., Zannini M., Bellacosa A., Tsichlis P.N., Fusco A., Santoro M. Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. Cancer Res. 60:2000;3916-3920.
49. de Vries J.E., Kornips F.H., Marx P., Bosman F.T., Geraedts J.P., ten Kate J. Transfected c-Ha-ras oncogene enhances karyotypic instability and integrates predominantly in aberrant chromosomes. Cancer Genet. Cytogenet. 67:1993;35-43.
50. Deleu S., Pirson I., Coulonval K., Drouin A., Taton M., Clermont F., Roger P.P., Nakamura T., Dumont J.E., Maenhaut C. IGF-1 or insulin, and the TSH cyclic AMP cascade separately control dog and human thyroid cell growth and DNA synthesis, and complement each other in inducing mitogenesis. Mol. Cell Endocrinol. 149:1999;41-51.
51. Della Fazia M.A., Servillo G., Sassone-Corsi P. Cyclic AMP signalling and cellular proliferation: regulation of CREB and CREM. FEBS Lett. 410:1997;22-24.
52. Derwahl M., Kuemmel M., Goretzki P., Schatz H., Broecker M. Expression of the human TSH receptor in a human thyroid carcinoma cell line that lacks an endogenous TSH receptor: growth inhibition by cAMP. Biochem. Biophys. Res. Commun. 191:1993;1131-1138.
53. Derwahl M., Manole D., Sobke A., Broecker M. Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms. Exp. Clin. Endocrinol. Diabet. 106(Suppl. 4):1998;S6-S9.
54. Domin J., Waterfield M.D. Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett. 410:1997;91-95.
55. Doskeland S.O., Maronde E., Gjertsen B.T. The genetic subtypes of cAMP-dependent protein kinase - functionally different or redundant? Biochim. Biophys. Acta. 1178:1993;249-258.
56. Downward J. Lipid-regulated kinases: some common themes at last. Science. 279:1998;673-674.
57. Dremier S., Pohl V., Poteet-Smith C., Roger P.P., Corbin J., Doskeland S.O., Dumont J.E., Maenhaut C. Activation of cyclic AMP-dependent kinase is required but may not be sufficient to mimic cyclic AMP-dependent DNA synthesis and thyroglobulin expression in dog thyroid cells. Mol. Cell Biol. 17:1997;6717-6726.
58. Dremier S., Vandeput F., Zwartkruis F.J., Bos J.L., Dumont J.E., Maenhaut C. Activation of the small G protein Rap1 in dog thyroid cells by both cAMP-dependent and -independent pathways. Biochem. Biophys. Res. Commun. 267:2000;7-11.
59. Dremier S., Coulonval K., Perpete S., Vandeput F., Fortemaison N., Van Keymeulen A., Deleu S., Ledent C., Clement S., Schurmans S., Dumont J.E., Lamy F., Roger P.P., Maenhaut C. The role of cyclic AMP and its effect on protein kinase A in the mitogenic action of thyrotropin on the thyroid cell. Ann. N. Y. Acad. Sci. 968:2002;106-121.
60. Dumont J.E., Maenhaut C., Pirson I., Baptist M., Roger P.P. Growth factors controlling the thyroid gland. Baillieres Clin. Endocrinol. Metab. 5:1991;727-754.
61. Dumont J.E., Lamy F., Roger P., Maenhaut C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol. Rev. 72:1992;667-697.
62. Edwards A.S., Scott J.D. A-kinase anchoring proteins: protein kinase A and beyond. Curr. Opin. Cell Biol. 12:2000;217-221.
63. Esapa C.T., Harris P.E. Mutation analysis of protein kinase A catalytic subunit in thyroid adenomas and pituitary tumours. Eur. J. Endocrinol. 141:1999;409-412.
64. Esapa C., Foster S., Johnson S., Jameson J.L., Kendall-Taylor P., Harris P.E. G protein and thyrotropin receptor mutations in thyroid neoplasia. J. Clin. Endocrinol. Metab. 82:1997;493-496.
65. Esapa C.T., Johnson S.J., Kendall-Taylor P., Lennard T.W., Harris P.E. Prevalence of Ras mutations in thyroid neoplasia. Clin. Endocrinol. (Oxford). 50:1999;529-535.
66. Fagin J.A. Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol. Endocrinol. 16:2002;903-911.
67. Farid N.R., Shi Y., Zou M. Molecular basis of thyroid cancer. Endocr. Rev. 15:1994;202-232.
68. Feliciello A., Giuliano P., Porcellini A., Garbi C., Obici S., Mele E., Angotti E., Grieco D., Amabile G., Cassano S., Li Y., Musti A.M., Rubin C.S., Gottesman M.E., Avvedimento E.V. The v-Ki-Ras oncogene alters cAMP nuclear signaling by regulating the location and the expression of cAMP-dependent protein kinase Iibeta. J. Biol. Chem. 271:1996;25350-25359.
69. Feliciello A., Gallo A., Mele E., Porcellini A., Troncone G., Garbi C., Gottesman M.E., Avvedimento E.V. The localization and activity of cAMP-dependent protein kinase affect cell cycle progression in thyroid cells. J. Biol. Chem. 275:2000;303-311.
70. Feliciello A., Gottesman M.E., Avvedimento E.V. The biological functions of A-kinase anchor proteins. J. Mol. Biol. 308:2001;99-114.
71. Field J.B., Ealey P.A., Marshall N.J., Cockcroft S. Thyroid-stimulating hormone stimulates increases in inositol phosphates as well as cyclic AMP in the FRTL-5 rat thyroid cell line. Biochem. J. 247:1987;519-524.
72. Filippa N., Sable C.L., Filloux C., Hemmings B., Van Obberghen E. Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Mol. Cell Biol. 19:1999;4989-5000.
73. Fournes B., Monier R., Michiels F., Milgrom E., Misrahi M., Feunteun J. Oncogenic potential of a mutant human thyrotropin receptor expressed in FRTL-5 cells. Oncogene. 16:1998;985-990.
74. Francis-Lang H., Zannini M., De Felice M., Berlingieri M.T., Fusco A., Di Lauro R. Multiple mechanisms of interference between transformation and differentiation in thyroid cells. Mol. Cell Biol. 12:1992;5793-5800.
75. Fujimoto J., Brenner-Gati L. Protein kinase-C activation during thyrotropin-stimulated proliferation of rat FRTL-5 thyroid cells. Endocrinology. 130:1992;1587-1592.
76. Fusco A., Pinto A., Tramontano D., Tajana G., Vecchio G., Tsuchida N. Block in the expression of differentiation markers of rat thyroid epithelial cells by transformation with Kirsten murine sarcoma virus. Cancer Res. 42:1982;618-626.
77. Fusco A., Berlingieri M.T., Di Fiore P.P., Portella G., Grieco M., Vecchio G. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol. Cell Biol. 7:1987;3365-3370.
78. Gallo A., Benusiglio E., Bonapace I.M., Feliciello A., Cassano S., Garbi C., Musti A.M., Gottesman M.E., Avvedimento E.V. v-ras and protein kinase C dedifferentiate thyroid cells by down-regulating nuclear cAMP-dependent protein kinase A. Genes Dev. 6:1992;1621-1630.
79. Gallo A., Feliciello A., Varrone A., Cerillo R., Gottesman M.E., Avvedimento V.E. Ki-ras oncogene interferes with the expression of cyclic AMP-dependent promoters. Cell Growth Differ. 6:1995;91-95.
80. Gerard C.M., Roger P.P., Dumont J.E. Thyroglobulin gene expression as a differentiation marker in primary cultures of calf thyroid cells. Mol. Cell Endocrinol. 61:1989;23-35.
81. Gire V., Wynford-Thomas D. RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene. 19:2000;737-744.
82. Gire V., Marshall C.J., Wynford-Thomas D. Activation of mitogen-activated protein kinase is necessary but not sufficient for proliferation of human thyroid epithelial cells induced by mutant Ras. Oncogene. 18:1999;4819-4832.
83. Gire V., Marshall C., Wynford-Thomas D. PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene. 19:2000;2269-2276.
84. Hall-Jackson C.A., Jones T., Eccles N.G., Dawson T.P., Bond J.A., Gescher A., Wynford-Thomas D. Induction of cell death by stimulation of protein kinase C in human epithelial cells expressing a mutant ras oncogene: a potential therapeutic target. Br. J. Cancer. 78:1998;641-651.
85. Hansen T.V., Rehfeld J.F., Nielsen F.C. Mitogen-activated protein kinase and protein kinase A signaling pathways stimulate cholecystokinin transcription via activation of cyclic adenosine 3′,5′-monophosphate response element-binding protein. Mol. Endocrinol. 13:1999;466-475.
86. Hatada T., Sakanoue Y., Kusunoki M., Kobayashi A., Utsunomiya J. Protein kinase C activity in human thyroid carcinoma and adenoma. Cancer. 70:1992;2918-2922.
87. Hoelting T., Tezelman S., Siperstein A.E., Duh Q.Y., Clark O.H. Thyrotropin stimulates invasion and growth of follicular thyroid cancer cells via PKC- rather than PKA-activation. Biochem. Biophys. Res. Commun. 195:1993;1230-1236.
88. Iacovelli L., Capobianco L., Salvatore L., Sallese M., D'Ancona G.M., De Blasi A. Thyrotropin activates mitogen-activated protein kinase pathway in FRTL-5 by a cAMP-dependent protein kinase A-independent mechanism. Mol. Pharmacol. 60:2001;924-933.
89. Ichikawa T., Kyprianou N., Isaacs J.T. Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection. Cancer Res. 50:1990;6349-6357.
90. Ichikawa T., Schalken J.A., Ichikawa Y., Steinberg G.D., Isaacs J.T. H-ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v-H-ras oncogene transfection. Prostate. 18:1991;163-172.
91. Ihle J.N. Cytokine receptor signalling. Nature. 377:1995;591-594.
92. Isozaki O., Emoto N., Tsushima T., Sato Y., Shizume K., Demura H., Akamizu T., Kohn L.D. Opposite regulation of deoxyribonucleic acid synthesis and iodide uptake in rat thyroid cells by basic fibroblast growth factor: correlation with opposite regulation of c-fos and thyrotropin receptor gene expression. Endocrinology. 131:1992;2723-2732.
93. Ivashkiv L.B. Cytokines and STATs: how can signals achieve specificity? Immunity. 3:1995;1-4.
94. Iyengar R. Gating by cyclic AMP: expanded role for an old signaling pathway. Science. 271:1996;461-463.
95. Jhon D.Y., Lee H.H., Park D., Lee C.W., Lee K.H., Yoo O.J., Rhee S.G. Cloning, sequencing, purification, and Gq-dependent activation of phospholipase C-beta 3. J. Biol. Chem. 268:1993;6654-6661.
96. Jones C.J., Kipling D., Morris M., Hepburn P., Skinner J., Bounacer A., Wyllie F.S., Ivan M., Bartek J., Wynford-Thomas D., Bond J.A. Evidence for a telomere-independent "clock" limiting RAS oncogene-driven proliferation of human thyroid epithelial cells. Mol. Cell Biol. 20:2000;5690-5699.
97. Joneson T., Bar-Sagi D. Ras effectors and their role in mitogenesis and oncogenesis. J. Mol. Med. 75:1997;587-593.
98. Kapeller R., Cantley L.C. Phosphatidylinositol 3-kinase. Bioessays. 16:1994;565-576.
99. Karga H., Lee J.K., Vickery A.L. Jr., Thor A., Gaz R.D., Jameson J.L. Ras oncogene mutations in benign and malignant thyroid neoplasms. J. Clin. Endocrinol. Metab. 73:1991;832-836.
100. Katz M.E., McCormick F. Signal transduction from multiple Ras effectors. Curr. Opin. Genet. Dev. 7:1997;75-79.
101. Katz A., Wu D., Simon M.I. Subunits beta gamma of heterotrimeric G protein activate beta 2 isoform of phospholipase C. Nature. 360:1992;686-689.
102. Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E., Gilbert C., Coffer P., Downward J., Evan G. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 385:1997;544-548.
103. Kawasaki H., Springett G.M., Mochizuki N., Toki S., Nakaya M., Matsuda M., Housman D.E., Graybiel A.M. A family of cAMP-binding proteins that directly activate Rap1. Science. 282:1998;2275-2279.
104. Kawasaki H., Springett G.M., Toki S., Canales J.J., Harlan P., Blumenstiel J.P., Chen E.J., Bany I.A., Mochizuki N., Ashbacher A., Matsuda M., Housman D.E., Graybiel A.M. A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13278-13283.
105. Khosravi-Far R., Der C.J. The Ras signal transduction pathway. Cancer Metastasis Rev. 13:1994;67-89.
106. Khosravi-Far R., Solski P.A., Clark G.J., Kinch M.S., Der C.J. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol. Cell Biol. 15:1995;6443-6453.
107. Khosravi-Far R., White M.A., Westwick J.K., Solski P.A., Chrzanowska-Wodnicka M., Van Aelst L., Wigler M.H., Der C.J. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol. Cell Biol. 16:1996;3923-3933.
108. Kikuchi A., Williams L.T. Regulation of interaction of ras p21 with RalGDS and Raf-1 by cyclic AMP-dependent protein kinase. J. Biol. Chem. 271:1996;588-594.
109. Kim S., Jee K., Kim D., Koh H., Chung J. Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1. J. Biol. Chem. 276:2001;12864-12870.
110. Kimura T., Van Keymeulen A., Golstein J., Fusco A., Dumont J.E., Roger P.P. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr. Rev. 22:2001;631-656.
111. Kirschner L.S., Sandrini F., Monbo J., Lin J.P., Carney J.A., Stratakis C.A. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex. Hum. Mol. Genet. 9:2000;3037-3046.
112. Kobayashi K., Shaver J.K., Liang W., Siperstein A.E., Duh Q.Y., Clark O.H. Increased phospholipase C activity in neoplastic thyroid membrane. Thyroid. 3:1993;25-29.
113. Kupperman E., Wen W., Meinkoth J.L. Inhibition of thyrotropin-stimulated DNA synthesis by microinjection of inhibitors of cellular Ras and cyclic AMP-dependent protein kinase. Mol. Cell Biol. 13:1993;4477-4484.
114. Kupperman E., Wofford D., Wen W., Meinkoth J.L. Ras inhibits thyroglobulin expression but not cyclic adenosine monophosphate-mediated signaling in Wistar rat thyrocytes. Endocrinology. 137:1996;96-104.
115. Laglia G., Zeiger M.A., Leipricht A., Caturegli P., Levine M.A., Kohn L.D., Saji M. Increased cyclic adenosine 3′,5′-monophosphate inhibits G protein-coupled activation of phospholipase C in rat FRTL-5 thyroid cells. Endocrinology. 137:1996;3170-3176.
116. Lamy F., Wilkin F., Baptist M., Posada J., Roger P.P., Dumont J.E. Phosphorylation of mitogen-activated protein kinases is involved in the epidermal growth factor and phorbol ester, but not in the thyrotropin/cAMP, thyroid mitogenic pathway. J. Biol. Chem. 268:1993;8398-8401.
117. Laugwitz K.L., Allgeier A., Offermanns S., Spicher K., Van Sande J., Dumont J.E., Schultz G. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc. Natl. Acad. Sci. U.S.A. 93:1996;116-120.
118. Laurent E., Mockel J., Van Sande J., Graff I., Dumont J.E. Dual activation by thyrotropin of the phospholipase C and cyclic AMP cascades in human thyroid. Mol. Cell Endocrinol. 52:1987;273-278.
119. Ledent C., Dumont J.E., Vassart G., Parmentier M. Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism. EMBO J. 11:1992;537-542.
120. Ledent C., Denef J.F., Cottecchia S., Lefkowitz R., Dumont J., Vassart G., Parmentier M. Costimulation of adenylyl cyclase and phospholipase C by a mutant alpha 1B-adrenergic receptor transgene promotes malignant transformation of thyroid follicular cells. Endocrinology. 138:1997;369-378.
121. Lemoine N.R., Mayall E.S., Wyllie F.S., Williams E.D., Goyns M., Stringer B., Wynford-Thomas D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene. 4:1989;159-164.
122. Lemoine N.R., Hughes C.M., Gullick W.J., Brown C.L., Wynford-Thomas D. Abnormalities of the EGF receptor system in human thyroid neoplasia. Int. J. Cancer. 49:1991;558-561.
123. Lombardi A., Veneziani B.M., Tramontano D., Ingbar S.H. Independent and interactive effects of tetradecanoyl phorbol acetate on growth and differentiated functions of FRTL5 cells. Endocrinology. 123:1988;1544-1552.
124. Lou L., Urbani J., Ribeiro-Neto F., Altschuler D.L. cAMP inhibition of Akt is mediated by activated and phosphorylated Rap1b. J. Biol. Chem. 277:2002;32799-32806.
125. Ludgate M., Gire V., Crisp M., Ajjan R., Weetman A., Ivan M., Wynford-Thomas D. Contrasting effects of activating mutations of GalphaS and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells. Oncogene. 18:1999;4798-4807.
126. Mansour S.J., Matten W.T., Hermann A.S., Candia J.M., Rong S., Fukasawa K., Vande Woude G.F., Ahn N.G. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 265:1994;966-970.
127. Marians R.C., Ng L., Blair H.C., Unger P., Graves P.N., Davies T.F. Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice. Proc. Natl. Acad. Sci. U.S.A. 99:2002;15776-15781.
128. Marshall C.J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Genet. Dev. 4:1994;82-89.
129. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 80:1995;179-185.
130. Marshall M.S. Ras target proteins in eukaryotic cells. FASEB J. 9:1995;1311-1318.
131. Marshall C.J. Ras effectors. Curr. Opin. Cell Biol. 8:1996;197-204.
132. Medina D.L., Santisteban P. Thyrotropin-dependent proliferation of in vitro rat thyroid cell systems. Eur. J. Endocrinol. 143:2000;161-178.
133. Medina D.L., Toro M.J., Santisteban P. Somatostatin interferes with thyrotropin-induced G1-S transition mediated by cAMP-dependent protein kinase and phosphatidylinositol 3-kinase. Involvement of RhoA and cyclin E x cyclin-dependent kinase 2 complexes. J. Biol. Chem. 275:2000;15549-15556.
134. Medina D.L., Rivas M., Cruz P., Barroso I., Regadera J., Santisteban P. RhoA activation promotes transformation and loss of thyroid cell differentiation interfering with thyroid transcription factor-1 activity. Mol. Endocrinol. 16:2002;33-44.
135. Meinkoth J.L., Goldsmith P.K., Spiegel A.M., Feramisco J.R., Burrow G.N. Inhibition of thyrotropin-induced DNA synthesis in thyroid follicular cells by microinjection of an antibody to the stimulatory G protein of adenylyl cyclase, Gs. J. Biol. Chem. 267:1992;13239-13245.
136. Metcalfe R.A., Findlay C., Robertson W.R., Weetman A.P., Mac Neil S. Differential effect of thyroid-stimulating hormone (TSH) on intracellular free calcium and cAMP in cells transfected with the human TSH receptor. J. Endocrinol. 157:1998;415-424.
137. Michel J.J., Scott J.D. AKAP mediated signal transduction. Annu. Rev. Pharmacol. Toxicol. 42:2002;235-257.
138. Michiels F.M., Caillou B., Talbot M., Dessarps-Freichey F., Maunoury M.T., Schlumberger M., Mercken L., Monier R., Feunteun J. Oncogenic potential of guanine nucleotide stimulatory factor alpha subunit in thyroid glands of transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 91:1994;10488-10492.
139. Miller M.J., Prigent S., Kupperman E., Rioux L., Park S.H., Feramisco J.R., White M.A., Rutkowski J.L., Meinkoth J.L. RalGDS functions in Ras- and cAMP-mediated growth stimulation. J. Biol. Chem. 272:1997;5600-5605.
140. Miller M.J., Rioux L., Prendergast G.V., Cannon S., White M.A., Meinkoth J.L. Differential effects of protein kinase A on Ras effector pathways. Mol. Cell Biol. 18:1998;3718-3726.
141. Mockel J., Laurent E., Lejeune C., Dumont J.E. Thyrotropin does not activate the phosphatidylinositol bisphosphate hydrolyzing phospholipase C in the dog thyroid. Mol. Cell Endocrinol. 82:1991;221-227.
142. Morrison D.K., Cutler R.E. The complexity of Raf-1 regulation. Curr. Opin. Cell Biol. 9:1997;174-179.
143. Muca C., Vallar L. Expression of mutationally activated G alpha s stimulates growth and differentiation of thyroid FRTL5 cells. Oncogene. 9:1994;3647-3653.
144. Namba H., Rubin S.A., Fagin J.A. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol. Endocrinol. 4:1990;1474-1479.
145. Nancy V., Wolthuis R.M., de Tand M.F., Janoueix-Lerosey I., Bos J.L., de Gunzburg J. Identification and characterization of potential effector molecules of the Ras-related GTPase Rap2. J. Biol. Chem. 274:1999;8737-8745.
146. Newton A.C. Regulation of protein kinase C. Curr. Opin. Cell Biol. 9:1997;161-167.
147. Nguyen L.Q., Kopp P., Martinson F., Stanfield K., Roth S.I., Jameson J.L. A dominant negative CREB (cAMP response element-binding protein) isoform inhibits thyrocyte growth, thyroid-specific gene expression, differentiation, and function. Mol. Endocrinol. 14:2000;1448-1461.
148. Ohno S., Akita Y., Hata A., Osada S., Kubo K., Konno Y., Akimoto K., Mizuno K., Saido T., Kuroki T.et al. Structural and functional diversities of a family of signal transducing protein kinases, protein kinase C family; two distinct classes of PKC, conventional cPKC and novel nPKC. Adv. Enzyme Regul. 31:1991;287-303.
149. Ohta K., Endo T., Onaya T. The mRNA levels of thyrotropin receptor, thyroglobulin and thyroid peroxidase in neoplastic human thyroid tissues. Biochem. Biophys. Res. Commun. 174:1991;1148-1153.
150. Ohta K., Pang X.P., Berg L., Hershman J.M. Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor. J. Clin. Endocrinol. Metab. 82:1997;2633-2638.
151. Oki N., Takahashi S.I., Hidaka H., Conti M. Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation. J. Biol. Chem. 275:2000;10831-10837.
152. Pages G., Brunet A., L'Allemain G., Pouyssegur J. Constitutive mutant and putative regulatory serine phosphorylation site of mammalian MAP kinase kinase (MEK1). EMBO J. 13:1994;3003-3010.
153. Park Y.J., Park E.S., Kim M.S., Kim T.Y., Lee H.S., Lee S., Jang I.S., Shong M., Park D.J., Cho B.Y. Involvement of the protein kinase C pathway in thyrotropin-induced STAT3 activation in FRTL-5 thyroid cells. Mol. Cell Endocrinol. 194:2002;77-84.
154. Parma J., Van Sande J., Swillens S., Tonacchera M., Dumont J., Vassart G. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades. Mol. Endocrinol. 9:1995;725-733.
155. Parma J., Duprez L., Van Sande J., Hermans J., Rocmans P., Van Vliet G., Costagliola S., Rodien P., Dumont J.E., Vassart G. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J. Clin. Endocrinol. Metab. 82:1997;2695-2701.
156. Peri A., Luciani P., Tonacchera M., Agretti P., Baglioni-Peri S., Buci L., Conforti B., Cioppi F., Biliotti G., Serio M., Vitti P., Chiovato L. Expression of cAMP-responsive element binding protein and inducible cAMP early repressor in hyperfunctioning thyroid adenomas. Eur. J. Endocrinol. 146:2002;759-766.
157. Pham N., Cheglakov I., Koch C.A., de Hoog C.L., Moran M.F., Rotin D. The guanine nucleotide exchange factor CNrasGEF activates ras in response to cAMP and cGMP. Curr. Biol. 10:2000;555-558.
158. Pierrat B., Correia J.S., Mary J.L., Tomas-Zuber M., Lesslauer W. RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase under dominant control of p38alpha mitogen-activated protein kinase (p38alphaMAPK). J. Biol. Chem. 273:1998;29661-29671.
159. Portella G., Vitagliano D., Li Z., Sferratore F., Santoro M., Vecchio G., Fusco A. TPA induces a block of differentiation and increases the susceptibility to neoplastic transformation of a rat thyroid epithelial cell line. Oncol. Res. 10:1998;441-447.
160. Postiglione M.P., Parlato R., Rodriguez-Mallon A., Rosica A., Mithbaokar P., Maresca M., Marians R.C., Davies T.F., Zannini M.S., De Felice M., Di Lauro R. Role of the thyroid-stimulating hormone receptor signaling in development
161. Prendergast G.C., Khosravi-Far R., Solski P.A., Kurzawa H., Lebowitz P.F., Der C.J. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene. 10:1995;2289-2296.
162. Prevostel C., Alvaro V., de Boisvilliers F., Martin A., Jaffiol C., Joubert D. The natural protein kinase C alpha mutant is present in human thyroid neoplasms. Oncogene. 11:1995;669-674.
163. Pruitt K., Der C.J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171:2001;1-10.
164. Pullen N., Thomas G. The modular phosphorylation and activation of p70s6k. FEBS Lett. 410:1997;78-82.
165. Qiu R.G., Chen J., Kirn D., McCormick F., Symons M. An essential role for Rac in Ras transformation. Nature. 374:1995;457-459.
166. Rameh L.E., Cantley L.C. The role of phosphoinositide 3-kinase lipid products in cell function. J. Biol. Chem. 274:1999;8347-8350.
167. Rapoport B. Dog thyroid cells in monolayer tissue culture: adenosine 3′,5′-cyclic monophosphate response to thyrotropic hormone. Endocrinology. 98:1976;1189-1197.
168. Raspe E., Laurent E., Corvilain B., Verjans B., Erneux C., Dumont J.E. Control of the intracellular Ca(2+)-concentration and the inositol phosphate accumulation in dog thyrocyte primary culture: evidence for different kinetics of Ca(2+)-phosphatidylinositol cascade activation and for involvement in the regulation of H2O2 production. J. Cell Physiol. 146:1991;242-250.
169. Raspe E., Reuse S., Roger P.P., Dumont J.E. Lack of correlation between the activation of the Ca(2+)-phosphatidylinositol cascade and the regulation of DNA synthesis in the dog thymocyte. Exp. Cell Res. 198:1992;17-26.
170. Ribeiro-Neto F., Urbani J., Lemee N., Lou L., Altschuler D.L. On the mitogenic properties of Rap1b: cAMP-induced G(1)/S entry requires activated and phosphorylated Rap1b. Proc. Natl. Acad. Sci. U.S.A. 99:2002;5418-5423.
171. Richards J.S. New signaling pathways for hormones and cyclic adenosine 3′,5′-monophosphate action in endocrine cells. Mol. Endocrinol. 15:2001;209-218.
172. Ringel M.D., Saji M., Schwindinger W.F., Segev D., Zeiger M.A., Levine M.A. Absence of activating mutations of the genes encoding the alpha-subunits of G11 and Gq in thyroid neoplasia. J. Clin. Endocrinol. Metab. 83:1998;554-559.
173. Rodriguez-Viciana P., Warne P.H., Dhand R., Vanhaesebroeck B., Gout I., Fry M.J., Waterfield M.D., Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 370:1994;527-532.
174. Roger P.P., Reuse S., Servais P., Van Heuverswyn B., Dumont J.E. Stimulation of cell proliferation and inhibition of differentiation expression by tumor-promoting phorbol esters in dog thyroid cells in primary culture. Cancer Res. 46:1986;898-906.
175. Roger P.P., Servais P., Dumont J.E. Regulation of dog thyroid epithelial cell cycle by forskolin, an adenylate cyclase activator. Exp. Cell Res. 172:1987;282-292.
176. Roger P., Taton M., Van Sande J., Dumont J.E. Mitogenic effects of thyrotropin and adenosine 3′,5′-monophosphate in differentiated normal human thyroid cells in vitro. J. Clin. Endocrinol. Metab. 66:1988;1158-1165.
177. Roger P.P., Demartin S., Dumont J.E. Nature of the critical labile event that controls RB phosphorylation in the cyclic AMP-dependent cell cycle of thyrocytes in primary culture. Exp. Cell Res. 252:1999;492-498.
178. Ros P., Rossi D.L., Acebron A., Santisteban P. Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis. Biochimie. 81:1999;389-396.
179. Rosenberg D., Groussin L., Jullian E., Perlemoine K., Bertagna X., Bertherat J. Role of the PKA-regulated transcription factor CREB in development and tumorigenesis of endocrine tissues. Ann. N. Y. Acad. Sci. 968:2002;65-74.
180. Russo D., Arturi F., Schlumberger M., Caillou B., Monier R., Filetti S., Suarez H.G. Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene. 11:1995;1907-1911.
181. Russo D., Arturi F., Wicker R., Chazenbalk G.D., Schlumberger M., DuVillard J.A., Caillou B., Monier R., Rapoport B., Filetti S.et al. Genetic alterations in thyroid hyperfunctioning adenomas. J. Clin. Endocrinol. Metab. 80:1995;1347-1351.
182. Saavedra H.I., Knauf J.A., Shirokawa J.M., Wang J., Ouyang B., Elisei R., Stambrook P.J., Fagin J.A. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene. 19:2000;3948-3954.
183. Saito J., Kohn A.D., Roth R.A., Noguchi Y., Tatsumo I., Hirai A., Suzuki K., Kohn L.D., Saji M., Ringel M.D. Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid. 11:2001;339-351.
184. Santelli G., de Franciscis V., Chiappetta G., D'Alessio A., Califano D., Mineo A., Monaco C., Vecchio G. Thyroid specific expression of the Ki-ras oncogene in transgenic mice. Adv. Exp. Med. Biol. 348:1993;59-62.
185. Santelli G., de Franciscis V., Portella G., Chiappetta G., D'Alessio A., Califano D., Rosati R., Mineo A., Monaco C., Manzo G.et al. Production of transgenic mice expressing the Ki-ras oncogene under the control of a thyroglobulin promoter. Cancer Res. 53:1993;5523-5527.
186. Saunier B., Tournier C., Jacquemin C., Pierre M. Stimulation of mitogen-activated protein kinase by thyrotropin in primary cultured human thyroid follicles. J. Biol. Chem. 270:1995;3693-3697.
187. Shaywitz A.J., Greenberg M.E. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 68:1999;821-861.
188. Shirokawa J.M., Elisei R., Knauf J.A., Hara T., Wang J., Saavedra H.I., Fagin J.A. Conditional apoptosis induced by oncogenic ras in thyroid cells. Mol. Endocrinol. 14:2000;1725-1738.
189. Sho K.M., Okajima F., Abdul Majid M., Kondo Y. Reciprocal modulation of thyrotropin actions by P1-purinergic agonists in FRTL-5 thyroid cells. Inhibition of cAMP pathway and stimulation of phospholipase C-Ca2+ pathway. J. Biol. Chem. 266:1991;12180-12184.
190. Spina A., Chiosi E., Illiano G., Berlingieri M.T., Fusco A., Grieco M. Protein kinase C activities are increased in rat thyroid epithelial cells expressing v-ras genes. Biochem. Biophys. Res. Commun. 157:1988;1093-1103.
191. Suarez H.G. Genetic alterations in human epithelial thyroid tumours. Clin. Endocrinol. (Oxford). 48:1998;531-546.
192. Szkudlinski M.W., Fremont V., Ronin C., Weintraub B.D. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol. Rev. 82:2002;473-502.
193. Tahara K., Grollman E.F., Saji M., Kohn L.D. Regulation of prostaglandin synthesis by thyrotropin, insulin or insulin-like growth factor-I, and serum in FRTL-5 rat thyroid cells. J. Biol. Chem. 266:1991;440-448.
194. Takahashi S., Conti M., Van Wyk J.J. Thyrotropin potentiation of insulin-like growth factor-I dependent deoxribonucleic acid synthesis in FRTL-5 cells: mediation by an autocrine amplification factor(s). Endocrinology. 126:1990;736-745.
195. Takahashi S.I., Nedachi T., Fukushima T., Umesaki K., Ito Y., Hakuno F., Van Wyk J.J., Conti M. Long-term hormonal regulation of the cAMP-specific phosphodiesterases in cultured FRTL-5 thyroid cells. Biochim. Biophys. Acta. 1540:2001;68-81.
196. Taylor S.S., Buechler J.A., Yonemoto W. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu. Rev. Biochem. 59:1990;971-1005.
197. Testa J.R., Bellacosa A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10983-10985.
198. Tsygankova O.M., Kupperman E., Wen W., Meinkoth J.L. Cyclic AMP activates Ras. Oncogene. 19:2000;3609-3615.
199. Tsygankova O.M., Saavedra A., Rebhun J.F., Quilliam L.A., Meinkoth J.L. Coordinated regulation of Rap1 and thyroid differentiation by cyclic AMP and protein kinase A. Mol. Cell Biol. 21:2001;1921-1929.
200. Urano T., Emkey R., Feig L.A. Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. EMBO J. 15:1996;810-816.
201. Uyttersprot N., Costagliola S., Dumont J.E., Miot F. Requirement for cAMP-response element (CRE) binding protein/CRE modulator transcription factors in thyrotropin-induced proliferation of dog thyroid cells in primary culture. Eur. J. Biochem. 259:1999;370-378.
202. Van Keymeulen A., Roger P.P., Dumont J.E., Dremier S. TSH and cAMP do not signal mitogenesis through Ras activation. Biochem. Biophys. Res. Commun. 273:2000;154-158.
203. Van Keymeulen A., Deleu S., Bartek J., Dumont J.E., Roger P.P. Respective roles of carbamylcholine and cyclic adenosine monophosphate in their synergistic regulation of cell cycle in thyroid primary cultures. Endocrinology. 142:2001;1251-1259.
204. Van Sande J., Parma J., Tonacchera M., Swillens S., Dumont J., Vassart G. Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J. Clin. Endocrinol. Metab. 80:1995;2577-2585.
205. Vanhaesebroeck B., Alessi D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346(Pt 3):2000;561-576.
206. Vanvooren V., Allgeier A., Nguyen M., Massart C., Parma J., Dumont J.E., Van Sande J. Mutation analysis of the Epac - Rap1 signaling pathway in cold thyroid follicular adenomas. Eur. J. Endocrinol. 144:2001;605-610.
207. Vassart G., Dumont J.E. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr. Rev. 13:1992;596-611.
208. Villone G., De Amicis F., Veneziani B.M., Salzano S., Di Carlo A., Tramontano D. Sustained versus transient cyclic AMP intracellular levels: effect on thyrotropin-dependent growth of thyroid cells. Cell Growth Differ. 8:1997;1181-1188.
209. Vojtek A.B., Hollenberg S.M., Cooper J.A. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell. 74:1993;205-214.
210. Wang X.D., Kiang J.G., Smallridge R.C. A phospholipase C inhibitor, U-73122, blocks TSH-induced inositol trisphosphate production, Ca2+ increase and arachidonic acid release in FRTL-5 thyroid cells. Biochim. Biophys. Acta. 1223:1994;101-106.
211. Wang S., Lloyd R.V., Hutzler M.J., Safran M.S., Patwardhan N.A., Khan A. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod. Pathol. 13:2000;882-887.
212. Wang L., Liu F., Adamo M.L. Cyclic AMP inhibits extracellular signal-regulated kinase and phosphatidylinositol 3-kinase/Akt pathways by inhibiting Rap1. J. Biol. Chem. 276:2001;37242-37249.
213. Warne P.H., Viciana P.R., Downward J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature. 364:1993;352-355.
214. Weber W., Hilz H. cAMP-dependent protein kinases I and II: divergent turnover of subunits. Biochemistry. 25:1986;5661-5667.
215. Weiss S.J., Philp N.J., Grollman E.F. Effect of thyrotropin on iodide efflux in FRTL-5 cells mediated by Ca2+. Endocrinology. 114:1984;1108-1113.
216. White M.A., Nicolette C., Minden A., Polverino A., Van Aelst L., Karin M., Wigler M.H. Multiple Ras functions can contribute to mammalian cell transformation. Cell. 80:1995;533-541.
217. White M.A., Vale T., Camonis J.H., Schaefer E., Wigler M.H. A role for the Ral guanine nucleotide dissociation stimulator in mediating Ras-induced transformation. J. Biol. Chem. 271:1996;16439-16442.
218. Whitmarsh A.J., Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74:1996;589-607.
219. Williams D.W., Williams E.D., Wynford-Thomas D. Loss of dependence on IGF-1 for proliferation of human thyroid adenoma cells. Br. J. Cancer. 57:1988;535-539.
220. Woloshin P.I., Walton K.M., Rehfuss R.P., Goodman R.H., Cone R.D. 3′,5′-Cyclic adenosine monophosphate-regulated enhancer binding (CREB) activity is required for normal growth and differentiated phenotype in the FRTL5 thyroid follicular cell line. Mol. Endocrinol. 6:1992;1725-1733.
221. Yamauchi J., Nagao M., Kaziro Y., Itoh H. Activation of p38 mitogen-activated protein kinase by signaling through G protein-coupled receptors. Involvement of Gbetagamma and Galphaq/11 subunits. J. Biol. Chem. 272:1997;27771-27777.
222. Yanagita Y., Okajima F., Sho K., Nagamachi Y., Kondo Y. An adenosine derivative cooperates with TSH and Graves' IgG to induce Ca2+ mobilization in single human thyroid cells. Mol. Cell Endocrinol. 118:1996;47-56.
223. Yuryev A., Wennogle L.P. The RAF family: an expanding network of post-translational controls and protein-protein interactions. Cell Res. 8:1998;81-98.
224. Zeiger M.A., Saji M., Gusev Y., Westra W.H., Takiyama Y., Dooley W.C., Kohn L.D., Levine M.A. Thyroid-specific expression of cholera toxin A1 subunit causes thyroid hyperplasia and hyperthyroidism in transgenic mice. Endocrinology. 138:1997;3133-3140.